회사 개요
P3 Health Partners Inc. is a patient-centered and physician-led population health management firm that delivers superior care services across the United States through its network of clinics and wellness centers. The company operates within the healthcare sector, specifically focusing on the medical care facilities industry, which implies a business model centered on direct patient service delivery and clinical operations. As of the latest reporting period, the firm holds a market capitalization of $597.32M and generates annual revenue of $1.46B, while specific employee headcount data is not publicly disclosed. These valuation and revenue figures indicate that the company occupies a significant position in the specialized healthcare services landscape, commanding nearly six hundred million dollars in market value to support its extensive operational footprint. The scale of operations reflected in the $1.46B revenue stream suggests a substantial footprint in the domestic market, positioning the entity as a meaningful player in the managed care and outpatient services space.
재무 건전성
The company reported revenue of $1.46B for the trailing twelve months, yet recorded a net income of $-147,948,000 and an EBITDA of $-186,138,000, revealing a substantial gap between top-line sales and bottom-line profitability. This significant disparity between revenue and negative net income indicates a challenging cost structure where operational expenses and depreciation likely exceed gross margins, resulting in overall losses despite high revenue generation. Despite the accounting losses, the company maintains positive free cash flow of $16.28M, which provides a degree of financial flexibility by generating internal liquidity to fund operations or repay debt without relying solely on external financing. The margin profile further illustrates financial pressure, with a gross margin of -4.1%, an operating margin of -40.0%, and a profit margin of -10.1%, all of which signal that the cost of goods sold and operating expenses are absorbing the majority of revenue. On the balance sheet, the company holds $25.01M in cash against $287.28M in debt, resulting in a debt-to-equity ratio that is not explicitly calculable from available data but highlights a highly leveraged position. The current ratio stands at 0.24, indicating that current assets are less than one-quarter of current liabilities, which points to potential short-term liquidity constraints and an inability to cover immediate obligations without refinancing or additional capital. Return on Equity is reported at -6952.6% and Return on Assets at -23.5%, metrics that reveal management has struggled to generate positive returns on the capital invested by shareholders or utilized in assets over the reporting period.
밸류에이션 평가
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is reported at -14.00, implying that analysts do not expect earnings to turn positive in the immediate future based on current models. The price-to-book ratio is -0.06, suggesting the stock trades at a significant discount to its book value, a common characteristic for distressed or unprofitable firms where market price falls below the net asset value. Alternative valuation measures such as the price-to-sales ratio of 0.41 and an EV/EBITDA of -1.54 provide context, indicating the market values the firm at less than half of its sales, which may reflect skepticism regarding future profitability or high risk premiums. In terms of trading range, the 52-week high is $11.30 and the 52-week low is $1.52, meaning the current price sits within a wide volatility band but is far from the peak levels achieved during the year. The stock exhibits a beta of 0.85, which indicates that the share price is slightly less volatile than the broader market, moving with about 15% less intensity than the general index in response to market fluctuations.
Growth & Income
Revenue growth for the year-over-year period is 3.8%, whereas earnings growth is N/A due to the company's continued negative net income, implying that top-line expansion has not yet translated into bottom-line accretion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all of its earnings rather than distributing them to shareholders. This reinvestment strategy is typical for growth-stage or turnaround companies that prioritize capital allocation toward operational improvements and debt reduction over returning cash to investors. The overall growth and income profile is characterized by modest revenue expansion in the absence of current profitability, with the company relying on cash flow generation and operational scaling to eventually achieve sustainable earnings growth and potentially initiate shareholder returns in the future.